Canada-based medical software company Tomoverse Imaging has closed its seed funding round, securing C$5m ($3.65m), for the development of tvCT, a platform aimed at enhancing the planning and execution of complex transcatheter cardiac procedures.
A significant Canadian Family Office spearheaded the seed funding round.
This platform is said to offer intuitive cloud-based tools that aid clinicians in improving patient care and procedural outcomes, as well as support interventional cardiology research.
It will integrate AI-based automated capabilities, enhancing accuracy in clinical workflows.
The capital injection will support the company in progressing clinical trials and obtaining clearances from Health Canada, the US Food and Drug Administration (FDA), and other regulatory authorities worldwide.
In addition, the funds will bolster the company’s strategic commercialisation efforts in North America and prime international markets.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTomoverse Imaging CEO Stuart Kozlick said: “We are deeply grateful for the trust and confidence placed in us by our investors.
“This strategic investment accelerates our product roadmap, enabling us to bring our innovative technology closer to patients and clinicians who need it most.”
The tvCT platform, which enables quick analysis of cardiac CT [computed tomography] images, has been designed to provide real-time results and is not yet granted approval for sale in any location.
The software’s user-friendly design and customisable features allow for easy access and adaptation to certain clinical requirements.
Tomoverse emphasises the security of patient data, ensuring that its cloud-based platform adheres to the highest security standards.
It focuses on advancing cardiac CT imaging solutions intended for structural heart and coronary interventions.
